J&J Enters Spine Robotics with Velys
J&J MedTech's Velys Active Robotic-Assisted System has gained FDA clearance for spinal fusion procedures, expanding beyond joint replacement. This strategic move allows J&J to compete in a larger segment of the surgical robotics market, leveraging the Velys platform's modularity and existing surgeon connections. Meanwhile, CEO J. Duato's 2025 compensation rose+Chairman/CEO+2025+Pay+Revealed) nearly 26% to $32.8 million.
The Velys system's new clearance covers a wide range of spinal procedures, including degenerative, tumor, trauma, and deformity cases. This positions J&J to challenge Medtronic and Stryker, who already have established robotic systems for spine surgery. J&J's entry into spine robotics was foreshadowed by the company's acquisition of Orthotaxy in 2018, which provided core technology for robotic surgery. The Velys system's open architecture allows surgeons to use their preferred implants, a key differentiator in the market. Prior to spinal applications, Velys was primarily used for knee replacement surgeries, with over 100,000 procedures completed. The expansion into spine surgery represents a significant growth opportunity, given the larger market size and increasing demand for minimally invasive procedures. J&J's CEO, Joaquin Duato, has emphasized innovation and strategic acquisitions as key drivers for growth. His compensation increase reflects the company's overall performance and strategic moves in the medical technology sector.
